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mRest and stress myocardial perfusion imaging, de-
scribed nearly 4 decades ago (1), is now performed
in 9 million people annually in the United States
(2). The procedure provides clinically useful data
regardless of whether the tracer is a monovalent
cation such as potassium, thallium, or rubidium; a
highly diffusible agent such as 15O-labeled water; an
amino acid precursor such as ammonia; or a lipo-
philic agent such as sestamibi or tetrofosmin. All of
the radiopharmaceuticals proposed to measure
myocardial perfusion, regardless of their chemical
composition, mechanism of uptake, or mechanism of
myocardial retention, follow the Sapirstein principle.
See page 285
In 1956, Sapirstein (3) described the behavior of
potassium-42 as an indicator to measure the distri-
bution of cardiac output:
“A foreign substance, after a single intravenous
administration, will be distributed initially to the
organs in proportion to their blood flow. The
substance will then be carried away from the organs
by their venous drainage. For a certain period of
time, however, the venous drainage will be negligi-
bly small compared to the arterial delivery. During
this time the fractional distribution of the substance
among the organs will correspond to the fractional
distribution of the cardiac output among them.”
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
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erfusion required an extraction fraction of 1 by the
rgan. Subsequent investigators demonstrated that
gents that are significantly retained by the organ,
ven with an extraction 1, still provide accurate
easurements of regional and absolute perfusion
4–6) and perfusion reserve (7,8), if imaging is
erformed before significant loss of indicator from
he tissue. Delayed imaging does not necessarily
eflect perfusion at the time of injection due to
ifferent rates of tracer clearance from normal and
schemic territories (9,10). For example, once in the
ell, monovalent cations, such as thallium, potas-
ium, and rubidium, reside in the cytoplasm, mixing
ith the intracellular potassium pool. These agents
re lost from the cell in proportion to their intra-
ellular concentration (greater loss from areas with
igher concentration). On the other hand, the
elative loss of tetrofosmin (11) and sestamibi (12)
s substantially slower than the monovalent cations
Table 1). Both technetium tracers are highly lipo-
hilic, with a1 charge distributed over the surface
f the molecule. These agents are retained by
inding to mitochondria. This mechanism of reten-
ion does not alter the value of these agents as
ndicators of perfusion. The potential additional
nformation related to retention may be useful to
valuate other diseases of the myocardium (see the
ollowing section).
Fast-forward to the second decade of the 21st
entury. Hybrid positron imaging devices such as
ositron emission tomography (PET) and com-
uted tomography (CT), provide high-resolution,
eadily quantified images. PET-CT myocardial
erfusion imaging offers data of higher diagnostic
uality than single-photon emission computed to-
ography, allowing greater certainty of interpreta-ion (13). Regional and global myocardial perfusion
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294reserve can be readily calculated from PET perfu-
sion data, providing additional information to eval-
uate flow-limiting arterial disease (14,15). The
short half-life of the most frequently used PET
perfusion agent, rubidium-82, has made pharmaco-
logic stress the standard (16). Despite higher quality
quantitative images, PET perfusion studies do not
provide information about a patient’s work capacity.
Exercise stress testing provides this prognostic in-
formation. Developing a positron-emitting radio-
pharmaceutical with a long enough half-life to
permit exercise stress testing would address this
problem. Preliminary data with the fluorine-18
labeled perfusion agent flurpiridaz, now in clinical
trials, suggest that it is useful for both detection of
regional myocardial perfusion abnormalities and
calculation of myocardial flow reserve (17,18).
Flurpiridaz is derived from the pharmacophore
pyridaben (used as an insecticide) (19). The radio-
labeled complex binds to mitochondria by interact-
ing with mitochondrial complex 1.
In this issue of iJACC, Gurm et al. (20) describe
the regional myocardial distribution of a new fluo-
rinated analog of tetraphenylphosphonium, [18F]-
uorophenyltriphosphonium (18F-TPP), as an in-
dicator of myocardial perfusion in pigs. The
intracellular distribution of tritiated tetraphenyl-
phosphonium was validated against microelectrode
measurements of mitochondrial transmembrane po-
tential in 1980 (21). In 1986, Fukuda et al. (22) used a
11C-labeled analog, 11C-triphenylmethylphosphonium
n dogs to determine myocardial membrane poten-
ial in vivo. After intravenous injection, 3% of the
ose localized in the myocardium within 2 min
nd remained constant for 100 min of imaging.
yocardial membrane potential of 148 mV was
alculated from the PET data (22). Although the
hort half-life of carbon-11 makes it impractical for
Table 1. Myocardial Percentage Injected Dose/Heart at 5 and
60 Min After Injection Comparing [18]F-TPP, Thallium-201,
Potassium-43, Rubidium-81, and Sestamibi
Agent (Ref. #) 5 Min 60 Min
[18]F-TPP (24) 2.19 2.13
Thallium-201 (25)* 2.66 0.73
Potassium 43 (25)*† 2.27 0.7
Rubidium-81 (25)* 1.56 0.54
Technetium-99m sestamibi (26)‡ 1 1
*In mice. †The 60-min potassium-43 data are extrapolated from measure-
ments at 40 and 160 min. ‡Based on normalized data from serial images in
human subjects. Sestamibi uptake based on region of interest analysis from
human subjects normalized to the 5-min uptake.
[18]F-TPP  [18F]-ﬂuorophenyltriphosphonium.linical use, Fukuda et al. (22) demonstrated theeasibility of myocardial imaging with 11C-triphenyl-
methylphosphonium. The agent traverses the car-
diomyocyte cell membrane due to its lipophilicity
and distributed charge and primarily localizes in
mitochondria in proportion to the mitochondrial
transmembrane potential (23). The rapid blood
clearance, uptake in the myocardium, and retention
suggest that the agent meets the criteria proposed
by Sapirstein.
Shoup et al. (24) demonstrated prompt myocar-
dial uptake and retention of a fluorinated analog of
tetraphenylphosphonium, F-Phe-TPP, in rats and
rabbits. Gurm et al. (20) confirmed the rapid blood
clearance and rapid, stable, myocardial uptake in
normal myocardium and ischemic tissue in pigs.
The investigators extend the observations of Shoup
et al. (24) by calculating mitochondrial transmem-
brane potential in the hearts of these animals with
severe myocardial ischemia.
Ischemia was induced by partial inflation of an
angioplasty balloon in the mid left anterior de-
scending coronary artery (sufficient obstruction of
flow to produce 1- to 2-mm ST-segment elevation
in the anterior precordial leads). Rhythm was sta-
bilized with amiodarone and lidocaine, and blood
pressure was stabilized with phenylephrine infusion.
Once stabilized, adenosine was infused intrave-
nously and continued for the duration of the exper-
iment. Phenylephrine infusion was adjusted as nec-
essary to maintain arterial pressure. After a second
injection of microspheres, F-Phe-TPP was admin-
istered intravenously and serial PET images were
recorded, and at the conclusion of the study, sam-
ples were counted.
The investigators observed an excellent correla-
tion between the distribution of relative perfusion as
measured by microspheres and relative distribution
of F-Phe-TPP (Fig. 3A in Gurm et al. [20]).
Unfortunately, there was no correlation with abso-
lute perfusion (Fig. 3B in Gurm et al. [20]). The
reason for this lack of correlation is unclear. It is
unlikely that this is due to a “roll-off” of extraction
because the data in Figure 5 (20) show that K1
(K1myocardial blood flow extraction fraction)
is relatively constant, even at flows 3 ml/min/g.
The stability of myocardial uptake shown by
Shoup et al. (24) and Gurm et al. (20) is important,
because the concentration of 18F-TPP in the lungs
decreases from 0.69% of the injected dose (ID)/g at
5 min to 0.36%ID/g at 30 min and in the liver from
0.34%ID/g at 5 min to 0.18%ID/g at 30 min. Thus,
a brief delay between tracer injection and imaging
should enhance the heart-to-background ratio, im-
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295proving detection of subtle regions of decreased
perfusion, but without concern about differential
myocardial tracer loss from redistribution. Table 1
summarizes myocardial retention of several perfu-
sion tracers at 5 and 60 min after injection.
In addition to the lack of correlation with abso-
lute flow, it is unclear why the calculated extraction
fraction of 18F-TPP is so low (0.26), and why
extraction did not decrease with adenosine infusion.
However, the uptake of F-Phe-TPP in normal
zones and in areas of ischemia is stable, as depicted
in Figures 6A and 6B in the Gurm et al. (20) study.
Clinical Implications
F-Phe-TPP rapidly localizes in the myocardium
and is retained without significant redistribution
over intervals of 30 min. Regional tracer distri-
bution mirrors relative myocardial perfusion. These
characteristics suggest that this agent will be useful
for myocardial perfusion imaging. Additional stud-
ies are needed to evaluate the low extraction fraction
and clarify the lack of correlation of F-Phe-TPP
uptake and absolute flow.
Myocardial retention that reflects mitochondrial
transmembrane potential may add information be-
yond that available from the measurement of per-
fusion alone. As cells undergo apoptosis, for exam-Nucl Med 1977;7:49–58.
1
1
parison betweendecreases, reducing retention of tracers that localize
in mitochondria (27). On the other hand, when
myocardium becomes ischemic, mitochondria be-
come hyperpolarized (28). These changes should be
reflected by changes in tracer retention.
In heart failure, for example, there is a significant
deficiency of mitochondrial adenosine triphosphate
production (29). Because sestamibi localizes in the
myocardium in proportion to the cell membrane
and mitochondrial transmembrane potential
(30,31), retention of the tracer in the heart may be
altered by heart failure. This concept was investi-
gated by Takehana et al. (32). These investigators
demonstrated an inverse relationship between the
rate of sestamibi clearance and left ventricular
ejection fraction in patients with dilated cardiomy-
opathy. It is likely that similar observations will be
made for F-Phe-TPP.
Based on the quality of the images and the
stability of myocardial uptake in the initial 30 min
of imaging, F-Phe-TPP deserves further evaluation
as an agent for imaging the myocardium.
Reprint requests and correspondence: Dr. H. William
Strauss, Nuclear Medicine Service, Memorial Sloan-
Kettering Cancer Center, Room S212, 1275 York Ave-
nue, New York, New York 10021. E-mail: straussh@ple, mitochondrial transmembrane potential mskcc.org.R E F E R E N C E S
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